Kyndryl Drops 9% in a Week as Shorts Hold Firm and Index Risk Looms

KD spent the week under pressure. The stock fell 9% over five sessions to close at $12.94, the sharpest weekly loss among its closest peers, and it arrived there carrying 14.3% short interest as a percentage of free float, one of the heavier bear positions in the IT services space. The interesting tension is not that short sellers are especially aggressive this week. It is that they are not retreating either, even as a fresh indexing question hangs over the name and the stock trades at valuations that look genuinely cheap relative to earnings.

Short interest is the starting point because at 14.3% of free float it demands attention. The position is stubborn rather than surging: it has crept up around 5% over the past month to roughly 32.6 million shares, but the week-on-week change is essentially flat, down just 0.3%. The borrow market itself is relaxed. Availability runs at nearly 903%, meaning there are roughly nine shares available to lend for every one already borrowed. That is well above the 52-week low of 390%, and cost to borrow is a negligible 0.56%. There is no short squeeze mechanics here. Options traders are similarly calm: the put/call ratio at 0.60 is marginally below its 20-day average of 0.63, putting it about three-quarters of a standard deviation on the bullish side. The prevailing picture from derivatives is not fear, it is mild indifference. With availability this loose and borrow costs this low, shorts can hold positions cheaply and without urgency, which may partly explain their reluctance to cover.

The Street's posture on KD is best described as cautiously neutral with a sceptical undertone. The most recent move on record came from JP Morgan's Tien-Tsin Huang in August, maintaining an Underweight rating while nudging his target from $13 to $14. Prior to that, Susquehanna downgraded the stock to Neutral in May and Scotiabank trimmed its target. Morgan Stanley cut its target dramatically from $28 to $13 back in March. The pattern across recent months is consistent: firms are not abandoning coverage, but they are lowering their expectations. The mean price target across the analyst community is $14.20, implying around 10% upside from the current price. That gap is real but modest, and the direction of travel on targets has been downward. The bull case centres on improving project profitability and IT infrastructure demand driving margin recovery. The bear case is harder to dismiss: revenue growth delays, a material weakness disclosure in internal controls, and several senior executive departures have all clouded visibility. Valuation factors do offer one genuinely interesting data point. The stock scores in the 96th percentile on earnings yield and 91st percentile on EV/EBIT across the ORTEX universe. The PE sits at 5.4x and EV/EBITDA at 1.9x, cheap multiples if the execution concerns prove manageable.

One institutional move worth noting is AQR Capital Management, which added nearly 2.9 million shares in the quarter to June to reach 6.6% of the class. D.E. Shaw also built a position of nearly 5 million shares in the same period. These are quant-driven shops, so the positions may reflect factor screens rather than a conviction view on Kyndryl's turnaround story. More notable is the Vanguard picture: The Vanguard Group, which previously held 12.4% of the class as a single entity, appears to have reorganised that stake across two separate Vanguard vehicles that filed fresh 13G disclosures in April. The combined Vanguard exposure is still material at around 13% of shares. No activist 13D filer is on the register. All 13D/G stakes are as last disclosed around the 5% threshold and holders falling below that level may not file again.

ORTEX flags a potential index event worth tracking for the December 2026 Quarterly Review. At its current market cap of $2.8 billion, KD sits in the S&P MidCap 400. ORTEX puts the probability of deletion from that index at 29%, requiring the stock to fall to around $18.36 for the exit rule to trigger. That price is well above where the stock trades now, so the exit line is not under immediate threat. ORTEX also puts a 31% probability on addition to the S&P SmallCap 600 at the same review, which would require the stock to drop to roughly $5.51 to qualify. Neither scenario is at the line today, but they describe the bracket within which the market cap story is being watched. If confirmed, deletion would bring an estimated $296 million of index-tracker selling over 5.7 days of normal volume on the trade date of December 18. Among the 39 past comparable MidCap 400 deletions, the median move from announcement to effective was minus 1%, with 51% moving in that direction.

Retail attention has picked up. Wikipedia page views for Kyndryl are running at a z-score of 2.1 against the company's own 90-day history, the highest in the tracked window. That is an attention signal, not a revenue indicator, but it aligns with this being an earnings week: KD reported on November 4 and the next scheduled event is February 2027. The peer comparison adds context to the week's move. DXC, the most closely correlated peer, fell even harder, down 13% on the week. EPAM and GLOB both managed gains of 3 to 7%. KD sat in the middle of the pack directionally but closer to the losers. The next thing to watch is whether the short position begins to unwind now that earnings are out, or whether the bears treat any post-results bounce as a re-entry opportunity given the still-unresolved questions around internal controls and the revenue growth outlook.